National Cancer Institute. Cancer Stat Facts: female breast cancer. https://seer.cancer.gov/statfacts/html/breast.html.

Feng Y, Spezia M, Huang S, Yuan C, Zeng Z, Zhang L, et al. Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. Genes Dis. 2018;5(2):77–106.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schwartz RS, Erban JK. Timing of metastasis in breast cancer. N Engl J Med. 2017;376(25):2486–8.

Article  PubMed  Google Scholar 

National Cancer Institute. Cancer stat facts: female breast cancer subtypes 2021. https://seer.cancer.gov/statfacts/html/breast-subtypes.html.

Dawood S, Broglio K, Buzdar AU, Hortobagyi GN, Giordano SH. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol. 2010;28(1):92–8.

Article  CAS  PubMed  Google Scholar 

Woods R, Yerushalmi R, Speers C, Tydesley S, Gelmon K. P5-14-17: stage IV at presentation—are HER2 positive tumors overrepresented? Cancer Res. 2011;71(24 Suppl):P5-14-7-P5-7.

Iqbal N, Iqbal N. Human epidermal growth factor receptor 2 (HER2) in cancers: Overexpression and therapeutic implications. Mol Biol Int. 2014;2014: 852748.

Article  PubMed  PubMed Central  Google Scholar 

Masaquel CHD, Barnett B, Krieger T, Pearson I, Copley-Merriman C, Kaye JA, Moy B. Clinical and economic burden of HER2-positive breast cancer recurrence in the US: a literature review [abstract]. Cancer Res. 2018;78(4_suppl):P3-10–4.

Google Scholar 

United States Food and Drug Administration. Highlights of prescibing information: HERCEPTIN (trastuzumab) 1998. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/103792s5250lbl.pdf.

United States Food and Drug Administration. Highlights of prescribing information: PERJETA (pertuzumab) 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125409s051lbl.pdf.

United States Food and Drug Administration. Highlights of prescribing information: MARGENZA (margetuximab-cmkb) 2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf.

United States Food and Drug Administration. Highlights of prescribing information: TYKERB (lapatinib) 2007. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022059s007lbl.pdf.

United States Food and Drug Administration. Highlights of prescribing information: NERLYNX (neratinib) 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208051s005s006lbl.pdf.

United States Food and Drug Administration. Highlights of prescribing information: TUKYSA (tucatinib) 2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213411s000lbl.pdf.

United States Food and Drug Administration. Highlights of prescribing information: KADCYLA (ado-trastuzumab emtansine) 2013. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125427s105lbl.pdf.

United States Food and Drug Administration. Highlights of prescribing information: ENHERTU (fam-trastuzumab deruxtecan-nxki) 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761139s011lbl.pdf.

Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer V.4.2023. © National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed 21 jul 2023.

Giordano SH, Franzoi MAB, Temin S, Anders CK, Chandarlapaty S, Crews JR, et al. Systemic therapy for advanced human epidermal growth factor receptor 2-positive breast cancer: ASCO guideline update. J Clin Oncol. 2022;40(23):2612–35.

Kaufman PA, Hurvitz SA, O’Shaughnessy J, Mason G, Yardley DA, Brufsky AM, et al. Baseline characteristics and first-line treatment patterns in patients with HER2-positive metastatic breast cancer in the SystHERs registry. Breast Cancer Res Treat. 2021;188(1):179–90.

Article  CAS  PubMed  Google Scholar 

Murthy RK, Loi S, Okines A, Paplomata E, Hamilton E, Hurvitz SA, et al. Tucatinib, trastuzumab, and capecitabine for her2-positive metastatic breast cancer. N Engl J Med. 2019;382(7):597–609.

Article  PubMed  Google Scholar 

Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367(19):1783–91.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Modi S, Saura C, Yamashita T, Park YH, Kim SB, Tamura K, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med. 2020;382(7):610–21.

Article  CAS  PubMed  Google Scholar 

Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355(26):2733–43.

Article  CAS  PubMed  Google Scholar 

Saura C, Oliveira M, Feng YH, Dai MS, Chen SW, Hurvitz SA, et al. Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: phase III NALA trial. J Clin Oncol. 2020;38(27):3138–49.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ramagopalan SV, Pisoni R, Zenin A, Rathore LS, Ray J, Sammon C. Comparative effectiveness of trastuzumab emtansine versus lapatinib plus chemotherapy for HER2+ metastatic breast cancer. J Comp Effective Res. 2021;10(7):595–602.

Article  Google Scholar 

Sanglier T, Fabi A, Flores C, Flahavan EM, Pena-Murillo C, Meyer AM, et al. T-DM1 after pertuzumab plus trastuzumab: treatment sequence-induced selection bias in HER2-positive metastatic breast cancer. Cancers (Basel). 2022;14(10):2468.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dev-Vartak P, Yu X, Liu F-Q, Cariola P, Hodge J, Gopalakrishnan V, et al. Using real world data to evaluate overall survival in PD1-treated vs standard of care metastatic melanoma patients. J Clin Oncol. 2018;36(15_suppl): e21606-e.

Article  Google Scholar 

Dalal AA, Gauthier G, Gagnon-Sanschagrin P, Burne R, Guérin A, Niravath P, et al. Treatment and monitoring patterns among premenopausal women with HR+/HER2− advanced breast cancer. Adv Ther. 2018;35(9):1356–67.

Article  CAS  PubMed  Google Scholar 

Moinard-Butot F, Saint-Martin C, Pflumio C, Carton M, Jacot W, Cottu PH, et al. Efficacy of trastuzumab emtansine (T-DM1) and lapatinib after dual HER2 inhibition with trastuzumab and pertuzumab in patient with metastatic breast cancer: Retrospective data from a French multicenter real-life cohort. Breast. 2022;63:54–60.

Article  PubMed  PubMed Central  Google Scholar 

Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015;372(8):724–34.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Angeli E, Bousquet G. Brain metastasis treatment: the place of tyrosine kinase inhibitors and how to facilitate their diffusion across the blood-brain barrier. Pharmaceutics. 2021;13(9):1446.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Krop IE, Lin NU, Blackwell K, Guardino E, Huober J, Lu M, et al. Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA. Ann Oncol. 2015;26(1):113–9.

Article  CAS  PubMed  Google Scholar 

Nader-Marta G, Martins-Branco D, Agostinetto E, Bruzzone M, Ceppi M, Danielli L, et al. Efficacy of tyrosine kinase inhibitors for the treatment of patients with HER2-positive breast cancer with brain metastases: a systematic review and meta-analysis. ESMO Open. 2022;7(3): 100501.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ciruelos EM, Díaz MN, Isla MD, López R, Bernabé R, González E, et al. Patient preference for oral chemotherapy in the treatment of metastatic breast and lung cancer. Eur J Cancer Care. 2019;28(6): e13164.

Article  Google Scholar 

Unger JM, Moseley A, Symington B, Chavez-MacGregor M, Ramsey SD, Hershman DL. Geographic distribution and survival outcomes for rural patients with cancer treated in clinical trials. JAMA Netw Open. 2018;1(4): e181235-e.

Article  Google Scholar 

Hurvitz SA, Hegg R, Chung W-P, Im S-A, Jacot W, Ganju V, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet. 2023;401(10371):105–17.

Article  CAS  PubMed  Google Scholar 

Kulukian A, Lee P, Taylor J, Rosler R, de Vries P, Watson D, et al. Preclinical activity of her2-selective tyrosine kinase inhibitor tucatinib as a single agent or in combination with trastuzumab or docetaxel in solid tumor models. Mol Cancer Ther. 2020;19(4):976–87.

Article  CAS  PubMed  Google Scholar 

Murthy RK, Loi S, Okines A, Paplomata E, Hamilton E, Hurvitz SA, et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med. 2020;382(7):597–609.

Article  CAS  PubMed  Google Scholar 

Rugo HS, Im S-A, Cardoso F, Cortes J, Curigliano G, Pegram MD, et al. Abstract GS1–02: Phase 3 SOPHIA study of margetuximab + chemotherapy vs trastuzumab + chemotherapy in patients with HER2+ metastatic breast cancer after prior anti-HER2 therapies: second interim overall survival analysis. Cancer Res. 2020;80(4_suppl):GS1-02-GS1-.

Google Scholar 

Saini KS, Twelves C. Determining lines of therapy in patients with solid cancers: a proposed new systematic and comprehensive framework. Br J Cancer. 2021;125(2):155–63.

Article  PubMed  PubMed Central  Google Scholar 

Perez EA, Hurvitz SA, Amler LC, Mundt KE, Ng V, Guardino E, et al. Relationship between HER2 expression and efficacy with first-line trastuzumab emtansine compared with trastuzumab plus docetaxel in TDM4450g: a randomized phase II study of patients with previously untreated HER2-positive metastatic breast cancer. Breast Cancer Res. 2014;16(3):R50.

Article  PubMed  PubMed Central  Google Scholar